Research programme: fatty acid amide hydrolase modulators - Evotec

Drug Profile

Research programme: fatty acid amide hydrolase modulators - Evotec

Alternative Names: RN-A; RN-B

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Renovis
  • Developer Evotec AG
  • Class
  • Mechanism of Action Fatty acid amide hydrolase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Germany
  • 01 Dec 2008 Pharmacodynamics data from a preclinical trial in Neurological disorders presented at the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
  • 03 May 2008 Renovis has been acquired by Evotec AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top